
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Previous close: Dr Reddy's Rs 1,388.00, Lupin Rs 1,950.00, Zydus Lifesciences Rs 1,204.20, Biocon Rs 359.40, Natco Pharma Rs 822.90.
Updated: 18 Nov 2026 • 10:29 am
Posted by:

Quick Answer
This Nifty Pharma stocks compared snapshot checks five names on price, valuation and Q2 FY27 results: Dr Reddy's, Lupin, Zydus Lifesciences, Biocon and Natco Pharma. Zydus Lifesciences is the largest by market capitalisation at Rs 1,18,713 crore. Lupin reports the highest return on equity at 21.65%. Nifty Pharma names differ in mix and scale, so read each multiple next to margins and returns.
Nifty Pharma stocks compared here means Dr Reddy's, Lupin, Zydus Lifesciences, Biocon and Natco Pharma on one page, checked on previous close, market value, valuation and the latest quarterly numbers. The group covers four large drug makers and a specialty maker, each with a different mix of exports, domestic sales and biosimilars, which is exactly why a side-by-side look helps.
All five companies have filed their September 2026 quarter, so every result below is Q2 FY27. Nifty Pharma stocks follow export demand, new launches and regulatory approvals, so a glance at the Nifty Pharma page and the Sensex page before you read the tables gives useful backdrop.
Click Here – Get Free Investment Predictions
Nifty Pharma Stocks Compared: Five Names on the List
The Nifty Pharma stocks compared here are Dr Reddy's, Lupin, Zydus Lifesciences, Biocon and Natco Pharma. Zydus Lifesciences is the largest by market capitalisation at Rs 1,18,713 crore. Previous closes run from Rs 359.40 for Biocon to Rs 1,950.00 for Lupin, which is why a side-by-side look at value rather than price is more useful.
| Stock | Previous close (Rs) | Market cap (Rs crore) |
|---|---|---|
| Dr Reddy's | 1,388.00 | 1,14,933 |
| Lupin | 1,950.00 | 92,419 |
| Zydus Lifesciences | 1,204.20 | 1,18,713 |
| Biocon | 359.40 | 59,956 |
| Natco Pharma | 822.90 | 15,866 |
A quick look at the business behind each ticker puts the numbers in context. Dr Reddy's makes generic and branded medicines, while Lupin makes generic and branded medicines. Zydus Lifesciences makes generic and branded medicines, and Biocon makes biosimilars and generic medicines. To compare Nifty Pharma stocks properly, line up price to earnings, return on equity and operating margin before forming a view.
Rounding out the group, Natco Pharma makes specialty and oncology medicines. A fair Nifty Pharma stock comparison looks at what each company actually earns from, not only at the share price. A broad maker and a specialty maker belong in separate mental boxes whenever you compare Nifty Pharma stocks fairly.
Nifty Pharma Stocks Valuation: Multiples, Returns and Payouts
Natco Pharma trades at the lowest price to earnings ratio in this group at 13.86. Lupin reports the highest return on equity at 21.65%. Natco Pharma has the lowest price to book value at 1.51. These Nifty Pharma stocks valuation readings come from the previous close and the latest reported financials. That is the idea behind this Nifty Pharma stocks compared table: price to earnings and return on equity sit side by side so a high or low reading stands out at once.
| Stock | Price to earnings | Price to book | ROE (%) | Dividend yield (%) | Debt to equity |
|---|---|---|---|---|---|
| Dr Reddy's | 41.65 | 2.96 | 7.21 | 0.58 | 0.19 |
| Lupin | 17.70 | 3.84 | 21.65 | 0.89 | 0.26 |
| Zydus Lifesciences | 27.59 | 4.27 | 15.10 | 0.08 | 0.50 |
| Biocon | 176.03 | 1.72 | 1.96 | 0.14 | 0.45 |
| Natco Pharma | 13.86 | 1.51 | 15.38 | 0.56 | 0.08 |
Price to earnings, return on equity, debt to equity and dividend yield give the clearest picture of valuation, returns and balance sheet room across the five names. Earnings per share and book value per share are the building blocks behind price to earnings and price to book, so a glance at both in each filing is time well spent. A simple Nifty Pharma stock comparison like this one is only as useful as the context behind it, which is why operating margin is worth checking as well.
In this group, price to earnings runs from 13.86 for Natco Pharma to 176.03 for Biocon. Lupin offers the highest dividend yield at 0.89%. Industry price to earnings readings differ by sub-sector: Dr Reddy's, Lupin, Zydus Lifesciences and Biocon at 40.71; Natco Pharma at 40.55. The industry price to earnings is a handy anchor: a stock above it is priced for faster growth, and one below it is priced for steadier earnings. A well-built Nifty Pharma stock comparison also notes that a single approval can move quarterly numbers.
Nifty Pharma Stocks Q2 FY27 Results: Revenue and Profit Check
Four of the five Nifty Pharma stocks compared have filed Q2 FY27 numbers. Zydus Lifesciences posted the fastest revenue growth at 29.0% year on year. Read revenue first and quarterly profit second, since the two together show how much of the growth reaches shareholders. The others are shown on their latest reported quarter, so read each one for what it is. Treat the Q2 FY27 numbers in this Nifty Pharma stocks compared review as a snapshot of one quarter, not a verdict on any pharma company.
| Stock | Q2 FY27 revenue (Rs crore) | Q2 FY26 revenue (Rs crore) | Q2 FY27 net profit (Rs crore) | Q2 FY26 net profit (Rs crore) |
|---|---|---|---|---|
| Dr Reddy's | 8,854 | 9,152 | ||
| Lupin | 7,954 | 7,138 | ||
| Zydus Lifesciences | 8,040 | 6,232 | ||
| Biocon | 4,423 | 4,388 |
Dr Reddy's Results Snapshot
Dr Reddy's reported Q2 FY27 revenue of Rs 8,854 crore for the September 2026 quarter.
Lupin Results Snapshot
In the September 2026 quarter, Lupin booked revenue of Rs 7,954 crore against Rs 7,138 crore in the same quarter last year, a rise of 11.4%.
Zydus Lifesciences Results Snapshot
Zydus Lifesciences' Q2 FY27 top line stood at Rs 8,040 crore, versus Rs 6,232 crore in Q2 FY26, a rise of 29.0%.
Biocon Results Snapshot
Biocon reported Q2 FY27 revenue of Rs 4,423 crore, compared with Rs 4,388 crore a year earlier, a rise of 0.8%.
Natco Pharma Results Snapshot
Natco Pharma has reported only its Q1 FY27 numbers so far, with revenue of Rs 794.4 crore for the June 2026 quarter. Its Q2 FY27 filing is yet to appear, so read the exchange disclosure when it lands before you set it against the others.
Launches, approvals and currency movement shape earnings, so each maker needs a look at its own results, so profit can look different from revenue in a single quarter. That is why a Nifty Pharma stock comparison works best when revenue and profit are read together across two or three quarters. Used this way, a Nifty Pharma stocks compared review becomes a map of the sector rather than a price list. When you compare Nifty Pharma stocks after each result season, track how operating margin changes from one quarter to the next.
Nifty Pharma Stocks Compared Two at a Time: Three Pairings
Readers rarely want a five-way table and nothing else, so here are three head-to-head reads drawn from the same data. Use them as a quick way to compare Nifty Pharma stocks two at a time.
Dr Reddy's vs Lupin
Dr Reddy's and Lupin both sell generic medicines in global markets. The two are close in size, with market capitalisations of Rs 1,14,933 crore for Dr Reddy's and Rs 92,419 crore for Lupin. On price to earnings, Lupin carries the lower multiple at 17.70 against 41.65 for Dr Reddy's. Lupin reports the higher return on equity, at 21.65% against 7.21% for Dr Reddy's. Two large makers with different mixes, so read margins next to valuation.
Zydus Lifesciences vs Biocon
Zydus Lifesciences sells a broad range of medicines, while Biocon focuses on biosimilars. On price to earnings, Zydus Lifesciences carries the lower multiple at 27.59 against 176.03 for Biocon. Zydus Lifesciences reports the higher return on equity, at 15.10% against 1.96% for Biocon. For dividend income, Biocon offers 0.14% against 0.08% at Zydus Lifesciences. A broad maker and a focused maker differ in mix, so compare returns first.
Natco Pharma vs Dr Reddy's
Natco Pharma focuses on specialty and oncology medicines, while Dr Reddy's is far broader. Dr Reddy's is about 7.2 times the size of Natco Pharma by market capitalisation, at Rs 1,14,933 crore against Rs 15,866 crore. Natco Pharma reports the higher return on equity, at 15.38% against 7.21% for Dr Reddy's. For dividend income, Dr Reddy's offers 0.58% against 0.56% at Natco Pharma. A specialty maker and a broad leader differ in scale, so read returns together.
Best Nifty Pharma Stocks for Each Type of Investor
Which of the best Nifty Pharma stocks is right for you depends on your priorities, so the table below lists the leader on each measure instead of crowning one name. Any Nifty Pharma stocks compared table can mislead if you stop at one row, because each pharma company leads on a different measure.
| If you care most about | Start your research with | The number |
|---|---|---|
| Lowest price to earnings | Natco Pharma | 13.86 |
| Highest return on equity | Lupin | 21.65% |
| Highest dividend yield | Lupin | 0.89% |
| Lowest price to book value | Natco Pharma | 1.51 |
| Largest by market capitalisation | Zydus Lifesciences | Rs 1,18,713 crore |
| Fastest Q2 FY27 revenue growth | Zydus Lifesciences | 29.0% |
No single name tops every row, which is exactly why a Nifty Pharma stock comparison helps. Margins, returns and valuation point to different companies, so decide what matters most to you before you rank the numbers.
What Is Driving Nifty Pharma Stocks Right Now?
The Nifty Pharma index tracks the large drug makers, so its names show how the sector is placed. Knowing what moves launches and regulatory approvals helps you compare Nifty Pharma stocks with the right questions in mind.
Export approvals, new launches and domestic sales decide earnings, so each maker has its own driver. A good Nifty Pharma stocks compared routine therefore tracks new launches, regulatory approvals and quarterly results.
Risks to Weigh When You Compare Nifty Pharma Stocks
Nifty Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Every Nifty Pharma stock comparison has blind spots, and for this group the biggest is launches and regulatory approvals.
Because new launches, regulatory approvals and quarterly results drive these businesses, the most useful habit is to read the management commentary that comes with every result and note what is expected for the next quarter.
How to Compare Nifty Pharma Stocks and Build a Shortlist
Start by deciding which drug maker mix you prefer, because each reads the market differently. Readers who follow new launches, regulatory approvals and quarterly results find the group easier to track. Done step by step, this Nifty Pharma stocks compared routine becomes repeatable rather than a one-off exercise.
Then check valuation and returns, because the five names rarely trade on the same multiple. A broad leader next to a specialty maker shows how the business behind each price changes the numbers. Keep the shortlist of best Nifty Pharma stocks short enough that you can actually follow each company's quarterly results.
The Univest stock screener lets you filter Nifty Pharma stocks by market capitalisation, return on equity and price to earnings, and the app keeps live prices a tap away through the trading day. Come back to this Nifty Pharma stocks compared page after the next set of results to see which numbers have moved.
Check the Univest Screener for live Nifty Pharma stock data
Download the Univest iOS App or Univest Android App to track these Nifty Pharma stocks live.
Conclusion: Nifty Pharma Stocks Compared at a Glance
This Nifty Pharma stocks compared review on price, valuation and Q2 FY27 results shows that no single name wins every measure. Zydus Lifesciences leads on size and Lupin leads on return on equity, while the others bring their own strengths. Treat the Nifty Pharma stocks Q2 FY27 results and Nifty Pharma stocks valuation tables as a research starting point, then check the filings and speak to a SEBI-registered advisor before you invest. If you plan to compare Nifty Pharma stocks again next quarter, the same checklist of price to earnings, return on equity and operating margin will work.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Nifty Pharma Stocks Compared
Which are the top Nifty Pharma stocks compared in this article?
Ans. The Nifty Pharma stocks compared in this article are Dr Reddy's, Lupin, Zydus Lifesciences, Biocon and Natco Pharma. They are checked on previous close, market capitalisation, price to earnings, price to book, return on equity and the latest quarterly results, so the group can be read in one sitting before you go deeper into any single company.
Which Nifty Pharma stock has the highest market capitalisation?
Ans. Among the five names, Zydus Lifesciences has the highest market capitalisation at Rs 1,18,713 crore. Dr Reddy's follows at Rs 1,14,933 crore. Market value changes with every price move, which means the ranking can shuffle, so look at the latest figure on the exchange.
Which of these Nifty Pharma stocks has the lowest price to earnings ratio?
Ans. On Nifty Pharma stocks valuation, Natco Pharma has the lowest price to earnings ratio among these Nifty Pharma stocks at 13.86, based on the latest reported earnings. Biocon sits at the other end at 176.03. Treat the lowest multiple as a place to start asking questions, because growth and business quality explain why investors pay more or less.
Which Nifty Pharma stock has the highest return on equity?
Ans. Lupin reports the highest return on equity in this group at 21.65%. In plain terms, return on equity tells you how hard shareholder funds are working. Read it across a few years and alongside debt, since a high ratio built on borrowing carries more risk.
How did Nifty Pharma stocks perform in Q2 FY27 results?
Ans. Four of the five names have filed Q2 FY27 numbers in our data. Zydus Lifesciences recorded the fastest revenue growth at 29.0% year on year. For Nifty Pharma stocks Q2 FY27 results, the others are covered on their latest reported quarter, and each filing on the exchange website carries the full detail.
What are the main risks when you compare Nifty Pharma stocks?
Ans. Nifty Pharma stocks depend on demand, input costs, policy and the wider market mood. Valuations differ by company, so read each filing for order, volume and margin commentary before you compare them. Keep an eye on new launches, regulatory approvals and quarterly results.
Which metrics matter most when you compare Nifty Pharma stocks?
Ans. Revenue growth, operating margin, return on equity and price to earnings matter most here. Compare each multiple with the company's own launch pipeline. Read each filing for export and launch commentary.
Which is the best Nifty Pharma stock to buy among these five?
Ans. The best Nifty Pharma stock depends on which drug maker mix you prefer, because the five names differ on all of these. On the numbers in this article, Zydus Lifesciences has the largest market capitalisation; Natco Pharma has the lowest price to earnings; Lupin has the highest return on equity as well as the highest dividend yield. There is no clear winner across every measure, and nothing here is a recommendation. Let the tables narrow your list, confirm the numbers in the filings, and take advice from a SEBI-registered advisor before acting.
Recent Articles

Top 3 Aerospace and Defence Stocks to Watch in 2027: HAL, BEL and Solar Industries
18 November 2026

3 Telecom IT Services Provider, Pistons Gaskets and Cooling Parts Maker and Medicines Exporter Stocks With a Strong Future Roadmap: Tech Mahindra, Banco Products (India) and Sun Pharma
17 November 2026

3 Airline Fare Software Provider, Visa Processing Firm and House Wires Producer Stocks With a Strong Future Roadmap: Accelya Solutions India, BLS International Services and RR Kabel
17 November 2026

3 Naval Shipbuilder, Diagnostics Centres Chain and Basmati Rice Company Stocks With a Strong Future Roadmap: Mazagon Dock Shipbuilders, Vijaya Diagnostic Centre and LT Foods
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top 3 Aerospace and Defence Stocks to Watch in 2027: HAL, BEL and Solar Industries
3 Telecom IT Services Provider, Pistons Gaskets and Cooling Parts Maker and Medicines Exporter Stocks With a Strong Future Roadmap: Tech Mahindra, Banco Products (India) and Sun Pharma
3 Airline Fare Software Provider, Visa Processing Firm and House Wires Producer Stocks With a Strong Future Roadmap: Accelya Solutions India, BLS International Services and RR Kabel
3 Naval Shipbuilder, Diagnostics Centres Chain and Basmati Rice Company Stocks With a Strong Future Roadmap: Mazagon Dock Shipbuilders, Vijaya Diagnostic Centre and LT Foods
3 Pathology Labs Network, Digital Engineering Firm and Stainless Pipes Maker Stocks With a Strong Future Roadmap: Thyrocare Technologies, Zensar Technologies and Ratnamani Metals and Tubes

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





